

Diagnosis and management of headaches in young people and adults

6th Guideline Development Group Meeting

National Clinical Guideline Centre

Date and Time: *17th June 2011 10:00 – 16:00*

Place: *NCGC, 180 Great Portland Street, London*

GDG Present: Martin Underwood (Chair)
Sam Chong
Brendan Davies
Mark Dunne-Willows
Carole Gavin
Devina Halsall
Kay Kennis
David Kernick
Manjit Matharu
Peter May
Wendy Thomas
William Whitehouse

NCGC Present: Sara Buckner (SB)
Serena Carville (SC)
Elisabetta Fenu (morning only)
Kate Kelley (KK)
Zahra Naqvi (ZN)
Smita Padhi (SP)
Tim Reason (TR)
Carlos Sharpin (CS)

NICE Present: Claire Turner

In attendance: Clifford Middleton, NICE (morning only)
Daria Bilan, NCGC

Minutes

1. **Introductions and apologies.** The Chair welcomed everyone to the meeting and noted apologies for Ria Bhola, and Norma O'Flynn. The GDG were informed that Kate Kelley from the NCGC was attending in Norma's absence.

The GDG were reminded to update their declarations of interest if any changes had occurred since the last meeting. Two GDG members notified changes.

The minutes of GDG 5 were agreed as an accurate reflection of the meeting, there were no matters arising.

2. **Economic model for the acute pharmacological treatment of migraine**
TR presented the economic model for the acute pharmacological treatment of migraine. The group discussed the evidence and finalised the recommendations drafted at GDG 5.
3. **Prophylactic pharmacological treatment of cluster headaches (Question 6).**
SB presented the clinical evidence for the prophylactic pharmacological treatment of cluster headaches. There was no economic evidence to report. The group discussed the evidence and drafted recommendations.
4. **Prophylactic pharmacological treatment of tension type headaches (Question 6).**
SP presented the clinical evidence for the prophylactic pharmacological treatment of tension type headaches. There was no economic evidence to report. The group discussed the evidence. Recommendations will be drafted when considering the evidence for non-pharmacological prophylactic treatment.
5. **Prophylactic pharmacological treatment of menstrual migraine (Question 6).**
SP presented the clinical evidence for the prophylactic pharmacological treatment of menstrual migraine. There was no economic evidence to report. The group discussed the evidence and drafted a recommendation. This will be re-visited when considering the evidence for contraceptive use and migraines.
6. **Prophylactic pharmacological treatment of migraine (Question 6).**
CS presented the clinical evidence for the prophylactic pharmacological treatment of migraine. The economic evidence will be presented after the non-pharmacological treatment has been reviewed. The group discussed the evidence and clarified queries. The recommendations will not be made until the economic evidence has been presented.
7. **Any other business.**
A brief presentation was given on how to use claromentis to allow the GDG to contribute to the writing of the guideline chapters.
The GDG were informed that the co-opted GDG members would be present at the next GDG meeting when the evidence for the non-pharmacological treatment of primary headaches would be reviewed.

Date, time and venue of the next meeting

Friday 15th July 2011, 10:00–16:00, National Clinical Guidelines Centre, 180 Great Portland Street, London